The insider buy is small and routine; it does not change the fundamental risk/reward for OKYO. The key catalyst remains the upcoming Phase 3 initiation for urcosimod in neuropathic corneal pain. Monitor for trial enrollment updates and any financing needs given the company's clinical-stage cash burn.
Price Chart
Executive Summary
OKYO Pharma's Chief Medical Officer Flavio Mantelli purchased 20,000 ordinary shares on Nasdaq at $1.40 per share, a $28,000 open-market buy. This is a modest insider vote of confidence from the CMO, but the dollar amount is small relative to a $49M market cap and does not signal material new information about the pipeline or upcoming Phase 3 trial for urcosimod.
Key Facts
- CMO Flavio Mantelli purchased 20,000 shares at $1.40 per share on Nasdaq on July 22, 2026
- Total purchase value is approximately $28,000
- Company plans to initiate a global Phase 3 pivotal trial for urcosimod in NCP in H2 2026 with ~111 patients
- Filing is incorporated by reference into the Company's F-3 registration statement (Reg. No. 333-293145)
Financial Impact
Insider purchase of $28,000 — negligible relative to $49M market cap
Risk Factors
- Insider purchase is too small to signal conviction — $28,000 is immaterial for a $49M market cap
- No financial data or pipeline updates provided in this filing
- Clinical-stage biotech with no approved products; Phase 3 trial carries binary risk
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001493152-26-034160 |
| Exhibit: ex99-1.htm | 0001493152-26-034160 |
| Document: 0001493152-26-034160-index-headers.html | 0001493152-26-034160 |
| Document: 0001493152-26-034160-index.html | 0001493152-26-034160 |
| Document: 0001493152-26-034160.txt | 0001493152-26-034160 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 6, 2026 21d ago | 6-K | $1.46 $1.41 | ▼ −3.42% | ▼ −3.18% | $1.44 (−1.37%) |
Oct 6, 2026 21d ago | Press Release | $1.46 $1.41 | ▼ −3.42% | ▼ −3.18% | $1.44 (−1.37%) |
Sep 29, 2026 28d ago | 6-K | $1.36 $1.29 | ▼ −5.15% | ▼ −4.94% | $1.44 (+5.88%) |
Sep 8, 2026 7w ago | 6-K | $1.53 $1.45 | ▼ −5.23% | ▼ −4.76% | $1.44 (−5.88%) |
Aug 7, 2026 11w ago | Insider Cluster | $1.57 $1.52 | ▼ −3.18% | ▼ −2.87% | $1.44 (−8.28%) |
Jul 28, 2026 13w ago | 6-K | $1.64 $1.64 | · 0.00% | ▲ +1.54% | $1.44 (−12.20%) |
Jul 27, 2026 13w ago | 6-K | $1.64 $1.64 | · 0.00% | ▼ −0.24% | $1.44 (−12.20%) |
Jul 23, 2026 13w ago | 6-K | $1.48 $1.55 | ▲ +4.73% | ▲ +4.63% | $1.44 (−2.70%) |
Jul 23, 2026 13w ago | Press Release | $1.48 $1.55 | ▲ +4.73% | ▲ +4.63% | $1.44 (−2.70%) |
Jul 23, 2026 13w ago | 6-K | $1.48 $1.55 | ▲ +4.73% | ▲ +4.63% | $1.44 (−2.70%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers